| Michaela Sky Mass, CF-SLP | |
|
1029 E Washington Ave, Mcalester, OK 74501-4849 | |
| (918) 423-2220 | |
| (918) 423-2620 |
| Full Name | Michaela Sky Mass |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1029 E Washington Ave, Mcalester, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215558614 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Provider Name | Ergonomic Consultants, Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1922039882 PECOS PAC ID: 6901809227 Enrollment ID: O20060807000018 |
News Archive
Leading research at Newcastle University has been used to shape how dentistry can be carried out safely during the Covid-19 pandemic by mitigating the risks of dental aerosols.
Merus Labs International Inc. is pleased to announce that their wholly owned subsidiary, Merus Labs Inc. announces the execution of a definitive agreement with Innocoll Pharmaceuticals Limited to license in, on an exclusive basis, 3 advanced wound care products for the Canadian market. Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
The center will be based around LUMICKS' C-Trap™ optical tweezers–fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs.
Among deployed U.S. service members who died of combat or unintentional injuries between 2001-2011 and underwent autopsies, the prevalence of coronary atherosclerosis was 8.5 percent, with factors associated with a higher prevalence of the disease including older age, lower educational level and prior diagnoses of dyslipidemia, hypertension, and obesity, according to a study in the December 26 issue of JAMA.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michaela Sky Mass, CF-SLP 3192 Old Savage Hwy, Hartshorne, OK 74547-5038 Ph: (918) 315-3675 | Michaela Sky Mass, CF-SLP 1029 E Washington Ave, Mcalester, OK 74501-4849 Ph: (918) 423-2220 |
News Archive
Leading research at Newcastle University has been used to shape how dentistry can be carried out safely during the Covid-19 pandemic by mitigating the risks of dental aerosols.
Merus Labs International Inc. is pleased to announce that their wholly owned subsidiary, Merus Labs Inc. announces the execution of a definitive agreement with Innocoll Pharmaceuticals Limited to license in, on an exclusive basis, 3 advanced wound care products for the Canadian market. Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).
The center will be based around LUMICKS' C-Trap™ optical tweezers–fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs.
Among deployed U.S. service members who died of combat or unintentional injuries between 2001-2011 and underwent autopsies, the prevalence of coronary atherosclerosis was 8.5 percent, with factors associated with a higher prevalence of the disease including older age, lower educational level and prior diagnoses of dyslipidemia, hypertension, and obesity, according to a study in the December 26 issue of JAMA.
› Verified 5 days ago
Mrs. Madison Walker, M.S. Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 1029 E Washington Ave, Mcalester, OK 74501 Phone: 918-423-2220 | |
Madelyn Rebekah Stanfield, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1029 E Washington Ave, Mcalester, OK 74501 Phone: 918-423-2220 | |
Landry Rehabilitation, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1223 Country Club Rd, Mcalester, OK 74501 Phone: 918-429-6734 | |
Melissa Lucille Byrum, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 407 E Cherokee Ave, Mcalester, OK 74501 Phone: 405-641-3534 | |
Joanne Ruth Hess, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 E Clark Bass Blvd, Mcalester, OK 74501 Phone: 918-426-1800 | |
Kelbie Moon, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1029 E Washington Ave, Mcalester, OK 74501 Phone: 918-423-2220 |